An observational study in Coronary Artery Disease, Myocardial Infarction and Acute Coronary Syndrome, sponsored by Queen Mary University of London. Recruiting at 1 site in United Kingdom. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.
Sponsored by Queen Mary University of London · Observational
There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes').
Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area.
Inflammation is the body's natural response to injury or infection. Importantly it is also involved in the development of CAD. Hormones such as oestrogen and testosterone are also likely to be contributory factors. The investigators think the differences between the way these hormones and inflammation play a part in CAD in both men and women are important, but the role they play is not yet fully understood.
In this study the investigators wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. The investigators will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. The investigators will combine this data with the data that is routinely collected during hospital admission. In this way the investigators hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research the investigators will address an under researched area and find new ways of treating women and men with coronary artery disease.
4,857 studies on the registry are indexed under Coronary Artery Disease; 890 are open to participants now.
This study's planned enrollment of 6,000 is above the median of 320 across 1,687 observational studies indexed under Coronary Artery Disease.
Browse Coronary Artery Disease studies →Queen Mary University of London is the lead sponsor of 253 studies on the registry; 58 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All patients attending Barts Heart Centre with chest pain
Inclusion criteria Any patient presenting with chest pain ≥16 years old presenting to Barts Heart Centre will be included.
Exclusion criteria Patients \<16 years old and Adults lacking capacity will be excluded. Patients where the cause of their chest pain presentation is not related to coronary artery disease e.g musculoskeletal chest pain, aortic dissection, gastrointestinal, pulmonary embolism
Mortality
Mortality at 30 days,1 year and 5 years, and relation to sex hormone/menstrual status/inflammatory profile
Time frame: 30 days/1 year/5 years
Re-admission
Re-admission rates post revascularization and relation to sex hormone/menstrual status/inflammatory profile
Time frame: 30 days/1 year/5 years
MACE
MACE post revascularisation and relation to sex hormone/menstrual status/inflammatory profile
Time frame: 30 days/1 year/5 years
Relationship with specific MI types
Relationship of sex hormone/menstrual status/inflammatory profile with specific types of ACS such as MINOCA
Time frame: 30 days/1 year/5 years
Relationship with inflammation
Relationship of sex hormone/menstrual status with markers of inflammation (e.g white cell count, CRP, D-dimer) and severity of disease (e.g troponin, extent of coronary disease)
Time frame: 30 days/1 year/5 years
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Queen Mary University of London →